The effects of LATS2 in LUAD may neutralize that in LUSC when the whole NSCLC patients were included; (2) a great heterogeneity is existed in lung cancer, especially in advanced-stage lung cancer, which may cause some bias. The gene discussed is LATS2; the disease is non-small cell lung carcinoma.